Compare Marsh & McLennan Companies, Inc. (MRSH) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Tempus AI — how do they compare? Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.05B), while Tempus AI trades at $55.53 (market cap $9.93B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 9.2× Tempus AI's market cap, and Marsh & McLennan Companies, Inc. pays a 2.08% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| MRSH | TEM | |
|---|---|---|
Market Cap | $91.05B | $9.93B |
Sector | Financials | Broad Market / Factor |
52-Week High | $211.21 | $103.25 |
52-Week Low | $157.32 | $41.55 |
Enterprise Value | $111.73B | $10.56B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $191.65, down 0.85% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.96 exceeding expectations. Revenue growth remains solid at 6% in Q2 2026, while the company maintains healthy profitability with a 14.24% net income margin. Recent acquisitions and AI investments highlight strategic growth initiatives.
The outlook for MRSH is positive, supported by earnings momentum and a consensus price target of $202.89 offering potential upside. However, margin pressure from rising expenses and soft P&C pricing present near-term risks. Institutional activity shows mixed sentiment, with some firms increasing stakes while others reduce holdings.
Tempus AI (TEM) trades at $52.05, up 12.86% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat revenue estimates and raised 2026 sales guidance. The stock is technically bullish with moving averages supporting upside, while fundamentals show revenue growth to $1.4 billion in 2026 but persistent net losses. Recent news highlights expansion through the Personalis acquisition and AI-driven precision medicine advancements.
Outlook: Growth prospects are robust with AI adoption in healthcare and strategic deals, but high valuation ratios and negative profitability pose risks. Analysts are bullish with a $61.57 consensus target, though cash burn and competitive pressures require monitoring for sustained investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
